Description
Glucagon-like peptide 2 (GLP-2) is an endogenous peptide hormone primarily synthesized in the intestine and pancreas. GLP-2 binds and activates the GLP-2 receptor, exhibiting vasodilatory, antihypertensive, antidepressant, and gastrointestinal motility modulating activities. In animal models, GLP-2 increases intestinal blood flow and decreases mean arterial blood pressure. GLP-2 potentiates L-type voltage-gated Ca2+ channels through a mechanism that involves activation of PKA. Additionally, GLP-2 decreases immobility time in animals undergoing the forced swim test. This peptide stimulates cell proliferation, inhibiting chemotherapy-induced mucosal atrophy in the intestines. GLP-2 also decreases gastric emptying and gastrointestinal motility.
References
Sasaki-Hamada S, Ito K, Oka JI. Neuronal Fos-like immunoreactivity associated with dexamethasone-induced hypertension in rats and effects of glucagon-like peptide-2. Life Sci. 2013 Oct 24. pii: S0024-3205(13)00618-8. [Epub ahead of print]. PMID: 24513200.
Hansen LB. GLP-2 and mesenteric blood flow. Dan Med J. 2013 May;60(5):B4634. PMID: 23673268.
Rasmussen AR, Viby NE, Hare KJ, et al. The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin. Dig Dis Sci. 2010 Oct;55(10):2785-96. PMID: 20112065.
Wang Y, Guan X. GLP-2 potentiates L-type Ca2+ channel activity associated with stimulated glucose uptake in hippocampal neurons. Am J Physiol Endocrinol Metab. 2010 Feb;298(2):E156-66. PMID: 19920220.
Iwai T, Hayashi Y, Narita S, et al. Antidepressant-like effects of glucagon-like peptide-2 in mice occur via monoamine pathways. Behav Brain Res. 2009 Dec 1;204(1):235-40. PMID: 19539656.
Mojsov S, Kopczynski MG, Habener JF. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem. 1990 May 15;265(14):8001-8. PMID: 1692320.
